EQS-News: Immunic to Participate in Scientific Conferences in October
NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October:
- NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October:
October 11-13: MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting. - The poster presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .
- Title: Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPhASIS Study
October 14-17: UEG (United European Gastroenterology) Week 2023. - Darius-Jean Namdjou, PhD, Head of Regulatory Affairs and Pharmacovigilance at Immunic, will speak during two sessions at this summit in Brussels, Belgium.